4-(3-Hydroxyphenyl)-2,4-dioxo-butanoic acid

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 4-(3-Hydroxyphenyl)-2,4-dioxo-butanoic acid
• 英文别名: 4-(3-hydroxyphenyl)-2,4-dioxobutanoic acid
• 化学式: C₁₀H₈O₅
• 分子量: 208.171
• InChiKey: PVTGWSQYMNAUSD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  15
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  91.7
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  ethyl 4-(m-hydroxyphenyl)-2,4-dioxobutyrate 在 sodium hydroxide 作用下， 以 四氢呋喃 、 甲醇 为溶剂， 反应 2.0h， 以47%的产率得到4-(3-Hydroxyphenyl)-2,4-dioxo-butanoic acid
  参考文献：
  名称：

  Design and synthesis of hybrids of diarylpyrimidines and diketo acids as HIV-1 inhibitors

  摘要：

  Based on the strategy of molecular hybridization, dilceto acid fragment as a classical phamacophore of integrase inhibitors was introduced to reverse transcriptase inhibitors diarylpyrimidines to design a series of diarylpyrimidine-diketo acid hybrids (DAPY-DICAs). The target molecules 10b and 11b showed inhibitory activities against WT HIV-1 with EC50 values of 0.18 mu M and 0.14 mu M, respectively. And the results of molecular docking demonstrated the potential binding mode and revealed that the DKA moiety and its ester could both be tolerated in the nonnucleoside binding site (NNBS) of HIV-1 RT. (C) 2017 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2017.03.009

文献信息

• Compositions and methods of double-targeting virus infections and cancer cells
  申请人：——

  公开号：US20020082242A1

  公开（公告）日：2002-06-27

  The invention includes compositions and methods useful for treatment of a virus infection in a mammal by double-targeting the virus (i.e. targeting the virus at more than one stage of the virus life cycle) and thereby inhibiting virus replication. The compositions of the invention include compounds, which comprise a phosphocholine moiety covalently conjugated with one or more therapeutic agents (e.g. nucleoside analogue, protease inhibitor, etc.) to a lipid backbone. The invention also includes pharmaceutical compositions for use in treatment of a virus infection in mammals. The methods of the invention comprise administering a compound of the invention, a pharmaceutically acceptable salt or a prodrug thereof, or a pharmaceutical composition of the invention, in an amount effective to treat the infection, to a mammal infected with a virus. Additionally, the invention includes compositions and methods useful for combating a cancer in a mammal and facilitating delivery of a therapeutic agent to a mammalian cell. The compositions of the invention include compounds, which comprise an alkyl lipid or phospholipid moiety covalently conjugated with a therapeutic agent (e.g., a nucleoside analogue). The invention also includes pharmaceutical compositions for combating cancer and facilitating delivery of a therapeutic agent to a mammalian cell. The methods of the invention comprise administering a compound of the invention, a pharmaceutically acceptable salt or a prodrug thereof, or a pharmaceutical composition of the invention, in an amount effective to combat a cancer or to facilitate delivery of a therapeutic agent to a mammalian cell.

  本发明涉及的组合物和方法可用于治疗哺乳动物病毒感染，通过双重靶向病毒（即在病毒生命周期的多个阶段靶向病毒），从而抑制病毒复制。本发明的组合物包括化合物，该化合物包括与一个或多个治疗剂（例如核苷类似物、蛋白酶抑制剂等）共价结合到脂质骨架上的磷酸胆碱基团。本发明还包括用于治疗哺乳动物病毒感染的制药组合物。本发明的方法包括向感染病毒的哺乳动物注射本发明的化合物、药学上可接受的盐或其前药，或本发明的制药组合物，以有效治疗感染。此外，本发明还包括用于对抗哺乳动物癌症和促进递送治疗剂到哺乳动物细胞的组合物和方法。本发明的组合物包括与治疗剂（例如核苷类似物）共价结合的烷基脂质或磷脂酰胆碱基团。本发明还包括用于对抗癌症和促进递送治疗剂到哺乳动物细胞的制药组合物。本发明的方法包括向哺乳动物注射本发明的化合物、药学上可接受的盐或其前药，或本发明的制药组合物，以有效对抗癌症或促进递送治疗剂到哺乳动物细胞。
• COMPOSITIONS AND METHODS OF DOUBLE-TARGETING VIRUS INFECTIONS AND CANCER CELLS
  申请人：WAKE FOREST UNIVERSITY

  公开号：EP1389970A2

  公开（公告）日：2004-02-25
• EP1389970A4
  申请人：——

  公开号：EP1389970A4

  公开（公告）日：2005-07-06
• US7026469B2
  申请人：——

  公开号：US7026469B2

  公开（公告）日：2006-04-11
• [EN] COMPOSITIONS AND METHODS OF DOUBLE-TARGETING VIRUS INFECTIONS AND CANCER CELLS<br/>[FR] COMPOSITIONS ET METHODES PERMETTANT UN DOUBLE CIBLAGE D'INFECTIONS VIRALES ET DE CELLULES CANCEREUSES
  申请人：UNIV WAKE FOREST

  公开号：WO2002087465A2

  公开（公告）日：2002-11-07

  The invention includes compositions and methods useful for treatment of a virus infection in a mammal by double-targeting the virus (i.e. targeting the virus at more than one stage of the virus life cycle) and thereby inhibiting virus replication. The compositions of the invention include compounds, which comprise a phosphocholine moiety covalently conjugated with one or more therapeutic agents (e.g. nucleoside analogue, protease inhibitor, etc.) to a lipid backbone. The invention also includes pharmaceutical compositions for use in treatment of a virus infection in mammals. The methods of the invention comprise administering a compound of the invention, a pharmaceutically acceptable salt or a prodrug thereof, or a pharmaceutical composition of the invention, in an amount effective to treat the infection, to a mammal infected with a virus. Additionally, the invention includes compositions and methods useful for combating a cancer in a mammal and facilitating delivery of a therapeutic agent to a mammalian cell. The compositions of the invention include compounds, which comprise an alkyl lipid or phospholipid moiety covalently conjugated with a therapeutic agent (e.g., a nucleoside analogue). The invention also includes pharmaceutical compositions for combating cancer and facilitating delivery of a therapeutic agent to a mammalian cell. The methods of the invention comprise administering a compound of the invention, a pharmaceutically acceptable salt or a prodrug thereof, or a pharmaceutical composition of the invention, in an amount effective to combat a cancer or to facilitate delivery of a therapeutic agent to a mammalian cell.